Gapping up
In reaction to earnings/guidance:
- SAM +8.8%, FFBC +8.3%, MAT +8%, BCS +6.9%, BOOM +6.6%, ABCB +4.8%, COF +4.2%, PKX +3.1%, NXGN +3%, TRTN +3%, VICR +2.3%, PBCT +2%, WAL +1.9%, ASB +1.8%, GBX +1.7%, SIVB +1.4%, ALV +1%
M&A news:
- CNX +2.1% (EQT may pursue takeover of CNX, according to Bloomberg)
- PYPL +0.9% (exploring acquisitions of cryptocurrency cos, according to Bloomberg)
Other news:
- IPHA +11.4% (doses first patient in Monalizumab Phase 3 clinical trial; triggers milestone payment)
- CVAC +7.6% (announces data from preclinical studies of its investigational SARS-CoV-2 vaccine candidate, CVnCoV, in mice and hamsters)
- KZR +6% (granted FDA Orphan Drug Designations for KZR-616 for the treatment of polymyositis and dermatomyositis)
- FUBO +4.9% (fuboTV rolls out updated Multiview feature on Apple TV)
- GILD +4.5% (confirms FDA approval of remdesivir for the treatment of COVID-19)
- AUPH +2.8% (announces data from Aurinia's AURA-LV and AURORA pivotal trials)
- HAS +2.1% (in sympathy with MAT earnings)
- AKBA +2.1% (presents results from INNO2VATE global Phase 3 program)
- FTAI +1.4% (to collaborate with LMT on The Module Factory)
- HHC +1.3% (announces proposal for Lower Manhattan's Seaport area)
- ZUO +1.2% (Hound Partners increases passive stake)
- AMD +1.2% (reacting to INTC earnings; INTC struggles favorable for AMD)
Analyst comments:
- CARG +4.8% (upgraded to Buy from Neutral at BTIG Research)
- FFIV +4.4% (upgraded to Buy from Neutral at MKM Partners)
- STNE +2.4% (upgraded to Positive from Neutral at Susquehanna)
- PHM +1.2% (upgraded to Positive from Neutral at Susquehanna; also upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- EOG +1% (upgraded to Overweight from Neutral at Piper Sandler)
- TPH +0.8% (upgraded to Buy from Neutral at B. Riley Securities)